All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
During the ESH 9th Translational Research Conference: Myeloproliferative Neoplasms, the MPN Hub was pleased to speak to Naveen Pemmaraju, MD Anderson Cancer Center, Houston, US. We asked, How should we define disease modification in myelofibrosis (MF)?
How should we define disease modification in MF?
Pemmaraju begins by explaining that since there is currently only one approved drug class for MF treatment (JAK inhibitors), the outcomes for patients can be variable. Pemmaraju goes on to discuss the importance of measuring disease, and how the introduction of new combination therapies could lead to new response criteria. Finally, Pemmaraju talks about a review article published in 'Cancer' earlier this year (2022), led by himself and Professor Adam J. Mead, University of Oxford, Oxford, UK.
Updates on non-JAK inhibitors for MF
Inhibiting the Janus kinase (JAK) pathway is considered the hallmark in treating myelofibrosis (MF); however, treatment discontinuation due to adverse events has been a concern. After JAK failure, therapeutic...
FREEDOM trial: How can we manage AEs associated with fedratinib?
During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Ruben A. Mesa, UT Health San Antonio, San Antonio, US. We asked, FREEDOM trial: How can we manage...
Subscribe to get the best content related to MPN delivered to your inbox